Original Article
A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice
Nurulain T. Zaveri,
Paul V. Marquez,
Michael E. Meyer,
Willma E. Polgar,
Abdul Hamid,
Kabirullah Lutfy,
Corresponding Author
Nurulain T. Zaveri
Astraea Therapeutics, LLC, Mountain View, California
Reprint requests: Nurulain T. Zaveri, PhD, Astraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, CA 94043; Tel.: 650-254-0786; Fax: 844-457-7470; E-mail: [email protected] and Kabirullah Lutfy, PhD, Western University of Health Sciences, 309 East 2nd Street Pomona, CA 91766; Tel.: 909-469-5481; Fax: 909-469-5600; E-mail: [email protected]Search for more papers by this authorPaul V. Marquez
College of Pharmacy, Western University of Health Sciences, Pomona, California
Search for more papers by this authorMichael E. Meyer
Astraea Therapeutics, LLC, Mountain View, California
Search for more papers by this authorWillma E. Polgar
Astraea Therapeutics, LLC, Mountain View, California
Search for more papers by this authorAbdul Hamid
College of Pharmacy, Western University of Health Sciences, Pomona, California
Search for more papers by this authorCorresponding Author
Kabirullah Lutfy
College of Pharmacy, Western University of Health Sciences, Pomona, California
Reprint requests: Nurulain T. Zaveri, PhD, Astraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, CA 94043; Tel.: 650-254-0786; Fax: 844-457-7470; E-mail: [email protected] and Kabirullah Lutfy, PhD, Western University of Health Sciences, 309 East 2nd Street Pomona, CA 91766; Tel.: 909-469-5481; Fax: 909-469-5600; E-mail: [email protected]Search for more papers by this authorNurulain T. Zaveri,
Paul V. Marquez,
Michael E. Meyer,
Willma E. Polgar,
Abdul Hamid,
Kabirullah Lutfy,
Corresponding Author
Nurulain T. Zaveri
Astraea Therapeutics, LLC, Mountain View, California
Reprint requests: Nurulain T. Zaveri, PhD, Astraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, CA 94043; Tel.: 650-254-0786; Fax: 844-457-7470; E-mail: [email protected] and Kabirullah Lutfy, PhD, Western University of Health Sciences, 309 East 2nd Street Pomona, CA 91766; Tel.: 909-469-5481; Fax: 909-469-5600; E-mail: [email protected]Search for more papers by this authorPaul V. Marquez
College of Pharmacy, Western University of Health Sciences, Pomona, California
Search for more papers by this authorMichael E. Meyer
Astraea Therapeutics, LLC, Mountain View, California
Search for more papers by this authorWillma E. Polgar
Astraea Therapeutics, LLC, Mountain View, California
Search for more papers by this authorAbdul Hamid
College of Pharmacy, Western University of Health Sciences, Pomona, California
Search for more papers by this authorCorresponding Author
Kabirullah Lutfy
College of Pharmacy, Western University of Health Sciences, Pomona, California
Reprint requests: Nurulain T. Zaveri, PhD, Astraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, CA 94043; Tel.: 650-254-0786; Fax: 844-457-7470; E-mail: [email protected] and Kabirullah Lutfy, PhD, Western University of Health Sciences, 309 East 2nd Street Pomona, CA 91766; Tel.: 909-469-5481; Fax: 909-469-5600; E-mail: [email protected]Search for more papers by this authorAbstract
Background
Nociceptin/orphanin FQ, the endogenous peptide agonist for the opioid receptor-like receptor (also known as NOP or the nociceptin receptor), has been shown to block the acquisition and expression of ethanol (EtOH)-induced conditioned place preference (CPP). Here, we report the characterization of a novel small-molecule NOP ligand AT-312 (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol) in receptor binding and GTPγS functional assays in vitro. We then investigated the effect of AT-312 on the rewarding action of EtOH in mice using the CPP paradigm. Further, using mice lacking the NOP receptor and their wild-type controls, we also examined the involvement of NOP in the effect of AT-312. Motivational effects of AT-312 alone were also assessed in the CPP paradigm.
Methods
Female mice lacking NOP and/or their wild-type controls received conditioning in the presence or absence of the NOP agonist [AT-312 (1, 3, and 10 mg/kg) or the control NOP agonist SCH221510 (10 mg/kg)] followed by saline/EtOH for 3 consecutive days (twice daily) and tested for CPP in a drug-free state on the next day.
Results
Our in vitro data showed that AT-312 is a high-affinity, selective NOP full agonist with 17-fold selectivity over the mu opioid receptor and >200-fold selectivity over the kappa opioid receptor. The results of our in vivo studies showed that AT-312 reduced EtOH CPP at the lowest dose (1 mg/kg) tested but completely abolished EtOH CPP at higher doses (3 or 10 mg/kg) compared to their vehicle-treated control group. AT-312 (3 mg/kg) did not alter EtOH-induced CPP in mice lacking NOP, confirming that AT-312 reduced EtOH CPP through its action at the NOP receptor. AT-312 (3 mg/kg) did not induce reward or aversion when administered alone, showing that the novel small-molecule NOP agonist shows efficacy in blocking EtOH-induced CPP via the NOP receptor.
Conclusions
Together, these data suggest that small-molecule NOP agonists have the potential to reduce alcohol reward and may be promising as medications to treat alcohol addiction.
Conflict of Interest
The authors declare no conflicts of interest. NTZ, WEP, and MEM are employees of Astraea Therapeutics.
References
- Altshuler HL, Phillips PE, Feinhandler DA (1980) Alteration of ethanol self-administration by naltrexone. Life Sci 26: 679–688.
- Aziz AM, Brothers S, Sartor G, Holm L, Heilig M, Wahlestedt C, Thorsell A (2016) The nociceptin/orphanin FQ receptor agonist SR-8993 as a candidate therapeutic for alcohol use disorders: validation in rat models. Psychopharmacology 233: 3553–3563.
- Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31–43.
- Benjamin D, Grant ER, Pohorecky LA (1993) Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 621: 137–140.
- Cheng Y-C, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.
- Ciccocioppo R, Angeletti S, Sanna PP, Weiss F, Massi M (2000) Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 404: 153–159.
- Ciccocioppo R, de Guglielmo G, Hansson AC, Ubaldi M, Kallupi M, Cruz MT, Oleata CS, Heilig M, Roberto M (2014a) Restraint stress alters nociceptin/orphanin FQ and CRF systems in the rat central amygdala: significance for anxiety-like behaviors. J Neurosci 34: 363–372.
- Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61: 4–12.
- Ciccocioppo R, Panocka I, Polidori C, Regoli D, Massi M (1999) Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology 141: 220–224.
- Ciccocioppo R, Polidori C, Antonelli L, Salvadori S, Guerrini R, Massi M (2002) Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides 23: 117–125.
- Ciccocioppo R, Stopponi S, Economidou D, Kuriyama M, Kinoshita H, Heilig M, Roberto M, Weiss F, Teshima K (2014b) Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat. Neuropsychopharmacology 39: 2601–2610.
- Devine DP, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H (1996) The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 727: 225–229.
- Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274–5278.
- Di Giannuario A, Pieretti S, Catalani A, Loizzo A (1999) Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats. Neurosci Lett 272: 183–186.
- Esser MB, Clayton H, Demissie Z, Kanny D, Brewer RD (2017) Current and binge drinking among high school students - United States, 1991–2015. MMWR Morb Mortal Wkly Rep 66: 474–478.
- Esser MB, Hedden SL, Kanny D, Brewer RD, Gfroerer JC, Naimi TS (2014) Prevalence of alcohol dependence among US adult drinkers, 2009-2011. Prev Chronic Dis 11: E206.
- Farren CK, O'Malley S (1997) Sequential use of naltrexone in the treatment of relapsing alcoholism. Am J Psychiatry 154: 714.
- Froehlich JC, Harts J, Lumeng L, Li TK (1990) Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 35: 385–390.
- Gianoulakis C (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4: 39–50.
- Gianoulakis C, de Waele JP, Thavundayil J (1996) Implication of the endogenous opioid system in excessive ethanol consumption. Alcohol 13: 19–23.
- Gilpin NW, Koob GF (2008) Neurobiology of alcohol dependence: focus on motivational mechanisms. Alcohol Res Health 31: 185–195.
- Hall FS, Sora I, Uhl GR (2001) Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology 154: 43–49.
- Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD (1986) Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 3: 39–54.
- Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD (1991) Opioidergic, serotonergic, and dopaminergic manipulations and rats’ intake of a sweetened alcoholic beverage. Alcohol 8: 355–367.
- Ji D, Gilpin NW, Richardson HN, Rivier CL, Koob GF (2008) Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 19: 1–12.
- Kallupi M, Scuppa G, de Guglielmo G, Calo G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R (2017) Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction. Neuropsychopharmacology 42: 695–706.
- Kallupi M, Varodayan FP, Oleata CS, Correia D, Luu G, Roberto M (2014) Nociceptin/orphanin FQ decreases glutamate transmission and blocks ethanol-induced effects in the central amygdala of naive and ethanol-dependent rats. Neuropsychopharmacology 39: 1081–1092.
- Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35: 217–238.
- Kornet M, Goosen C, Van Ree JM (1991) Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology 104: 367–376.
- Kotlinska J, Rafalski P, Biala G, Dylag T, Rolka K, Silberring J (2003) Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur J Pharmacol 474: 233–239.
- Kuzmin A, Kreek MJ, Bakalkin G, Liljequist S (2007) The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 32: 902–910.
- Kuzmin A, Sandin J, Terenius L, Ogren SO (2003) Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 304: 310–318.
- Lutfy K, Do T, Maidment NT (2001) Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology 154: 1–7.
- Lutfy K, Zaveri NT (2016) The nociceptin receptor as an emerging molecular target for cocaine addiction. Prog Mol Biol Transl Sci 137: 149–181.
- Marfaing-Jallat P, Miceli D, Le Magnen J (1983) Decrease in ethanol consumption by naloxone in naive and dependent rats. Pharmacol Biochem Behav 18(Suppl 1): 537–539.
- Marquez P, Borse J, Nguyen AT, Hamid A, Lutfy K (2008) The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience 155: 597–602.
- Mogil JS, Pasternak GW (2001) The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53: 381–415.
- Mokdad AH, Marks JS, Stroup DF, Gerberding JL (2004) Actual causes of death in the United States, 2000. JAMA 291: 1238–1245.
- Murphy NP, Lee Y, Maidment NT (1999) Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832: 168–170.
- Murphy NP, Ly HT, Maidment NT (1996) Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 75: 1–4.
- Murphy NP, Maidment NT (1999) Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem 73: 179–186.
- Murphy NP, Tan AM, Lam HA, Maidment NT (2004) Nociceptin/orphanin FQ modulation of rat midbrain dopamine neurons in primary culture. Neuroscience 127: 929–940.
10.1016/j.neuroscience.2004.05.055 Google Scholar
- Myers RD, Borg S, Mossberg R (1986) Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 3: 383–388.
- Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, Watson SJ Jr (1999a) Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412: 563–605.
10.1002/(SICI)1096-9861(19991004)412:4<563::AID-CNE2>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson SJ Jr (1999b) Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 406: 503–547.
10.1002/(SICI)1096-9861(19990419)406:4<503::AID-CNE7>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- Nguyen K, Tseng A, Marquez P, Hamid A, Lutfy K (2012) The role of endogenous dynorphin in ethanol-induced state-dependent CPP. Behav Brain Res 227: 58–63.
- Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J, Takeshima H, Nukada T, Nabeshima T, Yamashita T, Noda T, Sugimoto T (1997) Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor. EMBO J 16: 1858–1864.
- O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160: 19–29.
- Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5: 324–332.
- Oswald LM, Wand GS (2004) Opioids and alcoholism. Physiol Behav 81: 339–358.
- Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, Gold LH (2000) mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 293: 1002–1008.
- Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jimenez A, Benito A, Pedregal C, Weiss F, Statnick MA (2016) A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol seeking in animal models. Alcohol Clin Exp Res 40: 945–954.
- Sakoori K, Murphy NP (2004) Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology 172: 129–136.
- Samson HH, Doyle TF (1985) Oral ethanol self-administration in the rat: effect of naloxone. Pharmacol Biochem Behav 22: 91–99.
- Statnick MA, Chen Y, Ansonoff M, Witkin JM, Rorick-Kehn L, Suter TM, Song M, Hu C, Lafuente C, Jimenez A, Benito A, Diaz N, Martinez-Grau MA, Toledo MA, Pintar JE (2016) A novel nociceptin receptor antagonist LY2940094 inhibits excessive feeding behavior in rodents: a possible mechanism for the treatment of binge eating disorder. J Pharmacol Exp Ther 356: 493–502.
- Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT (2009) Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther 331: 954–964.
- Traynor JR, Nahorski SR (1995) Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47: 848–854.
- Tseng A, Nguyen K, Hamid A, Garg M, Marquez P, Lutfy K (2013) The role of endogenous beta-endorphin and enkephalins in ethanol reward. Neuropharmacology 73: 290–300.
- Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ (2008) The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther 326: 672–682.
- Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880.
- Volpicelli JR, Davis MA, Olgin JE (1986) Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 38: 841–847.
- Weiss F, Mitchiner M, Bloom FE, Koob GF (1990) Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology 101: 178–186.
- Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R (2014) The biology of nociceptin/orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141: 283–299.
- Zaveri NT (2011) The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem 11: 1151–1156.
- Zaveri NT (2016) Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility. J Med Chem 59: 7011–7028.
- Zaveri N, Polgar WE, Olsen CM, Kelson AB, Grundt P, Lewis JW, Toll L (2001) Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 428: 29–36.
